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Abstract. Epidermal-mesenchymal transition (EMT) confers 
an advantage to cancer cells by improving their invasive 
capacity and metastatic potential. This phenomenon by which 
epidermal cells change into mesenchymal cells and therefore 
acquire a higher ability to automaticity, is considered a key 
process in cancer development. Transforming growth factor-β 
(TGF-β) is a significant factor for accelerating EMT through 
the activation of proteins, including members of the Smad 
pathway. Furthermore, previous studies have shown that 
low-dose paclitaxel (PTX) inhibits EMT in certain cell lines, 
including those of cancer cells. The present study determined 
whether low-dose PTX was able to inhibit EMT in a human 
cholangiocarcinoma CCKS-1 cell line that had been treated 
with TGF-β1. First, the cytotoxic concentration of PTX for the 
CCKS‑1 cells was identified to be ~5 nM by MTT assay and 
dead cell staining. Therefore, the concentrations of PTX were 
set as 1 nM, 2.5 nM and 5 nM for the subsequent experiments. 
In the morphological investigation, the CCKS-1 cells changed 
into a spindle morphology and became separated by the 
administration of TGF-β1. However, low-dose PTX inhibited 
these changes and the morphology resembled the control cells 
in a dose‑dependent manner. Similarly, immunofluorescence 
and immunoblotting investigations revealed that the CCKS-1 
cells expressed mesenchymal markers following the admin-
istration of TGF-β1. However, low-dose PTX inhibited the 
expression of the mesenchymal markers and the CCKS-1 cells 
expressed the epithelial marker, E-cadherin. In particular, a 
concentration-dependent effect was observed in the immu-
noblotting experiments. These results show that PTX may be 
able to inhibit EMT in cancer cells, depending on the dose 
concentration.
Introduction
Cholangiocarcinoma is one of the most lethal malignant 
tumors (1), as it is difficult to diagnose in the early stages. 
Since symptoms develop later, patients are often diagnosed 
when the cancer is at a metastatic stage (2,3). Numerous other 
malignant tumors are also difficult to diagnose in their early 
stages. As a result, identifying a method of curative therapy 
for advanced-stage tumors is urgently required. Invasion and 
metastasis are significant factors in the advanced stages of 
tumors. The inhibition of these phenomena may enhance the 
treatment outcome of malignant tumors and also allow the 
patient to be treated with a resection or using chemotherapy, 
thus inhibiting the appearance of new lesions despite being at 
an advanced stage.
Epidermal-mesenchymal transition (EMT) is a process 
whereby epidermal cells exhibit reduced intercellular adhesion 
and acquire fibroblast‑like properties (4). This phenomenon is 
common to normal development and carcinogenesis, and is 
associated with mechanisms that induce tumor invasion and 
metastasis (5). By this process, epidermal cells are converted 
to cells that display mesenchymal features and become 
dedifferentiated and malignant. Biological markers of EMT 
include a decrease in the level of epithelial markers, including 
E-cadherin, and the expression of mesenchymal markers, 
including N-cadherin, vimentin and α-smooth muscle actin 
(α-SMA) (6-8). Furthermore, transforming growth factor-β 
(TGF-β) induces EMT in tumor cells, activating the TGF-β 
signaling pathway, which includes the Smad proteins and also 
the non-Smad pathways (9,10). 
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In contrast, certain studies have demonstrated that pacli-
taxel (PTX), one of the major anticancer agents that stabilizes 
microtubules and arrests the cell cycle in the G0/G1 and G2/M 
phases (11,12), inhibits the invasive ability of breast cancer cell 
lines when used in low‑doses (13,14). Furthermore, certain 
studies have revealed that low-dose PTX inhibits TGF-β/Smad 
activity in fibrosis (15,16). Based on these findings, the present 
study hypothesized that low-dose PTX may inhibit the induc-
tion of EMT by TGF-β1 in the human cholangiocarcinoma 
CCKS-1 cell line.
Materials and methods
Reagents. PTX (moleculer weight, 853.91; Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA) and TGF-β1 
(Sigma-Aldrich, St. Louis, MO, USA) were used.
Antibodies. Mouse monoclonal antibodies for N-cadherin, 
E-cadherin, α‑SMA, β-catenin and vimentin were used as 
primary antibodies. A rabbit monoclonal antibody was used 
for N-cadherin and a goat polyclonal antibody for phosphory-
lated (p)-Smad2/3 (Santa Cruz Biotechnology, Inc.).
Cell culture. A human ICC cell line, CCKS-1, obtained from 
the Department of Human Pathology, Kanazawa University 
Graduate School of Medicine (Kanazawa, Ishikawa, 
Japan) (17,18) was used. The ICC cell line was maintained at 
37˚C in a 5% CO2 incubator and grown in RPMI‑1640 medium 
supplemented with 2 mM glutamine, 1% fetal bovine serum 
(FBS; Nichirei Biosciences, Inc., Tokyo, Japan), 100 U/l peni-
cillin and 100 µg/ml streptomycin (Invitrogen, Carlsbad, CA, 
USA).
Cell proliferation assay. The proliferative effect of PTX on 
the ICC cell lines was quantified using an MTT colorimetric 
assay with Cell Proliferation kit I (Roche, West Sussex, 
UK), according to the manufacturer's instructions. In brief, 
the CCKS-1 cells (5x103 cells/well) were grown in 96-well 
flat‑bottom microtiter plates in 100 µl medium containing 1% 
FBS and incubated for 12 h at 37˚C in a humidified atmosphere 
with 5% CO2. Following the incubation period, the medium 
was exchanged for a new medium containing 1% FBS, 5 ng/ml 
TGF-β1 and/or various concentrations (1-100 nM) of PTX. 
The mixture was incubated for 72 h and the resultant absor-
bance was recorded at 562 nm using a 96-well plate reader 
(Multiskan GO; Thermo Scientific, Waltham, MA, USA). The 
data are represented as the mean ± SD of three independent 
experiments and expressed as a percentage of the untreated 
control cells.
Cell death assay. The cytotoxic effect of PTX on the ICC cell 
lines was quantified by flow cytometry using Pacific Blue™ 
annexin V and SYTOX® AADvanced™ dead cell stain 
(Invitrogen), according to the manufacturer's instructions. In 
brief, the CCKS-1 cells were cultured in a medium containing 
10% FBS. Following the culture, the medium was exchanged 
for new medium containing 1% FBS and/or various concentra-
tions of PTX with 5 ng/ml TGF-β1 (control, 5 ng/ml TGF-β1 
only; 1 nM PTX + TGF-β1; 2.5 nM PTX + TGF-β1; 5nM 
PTX + TGF-β1; and 10 nM PTX + TGF-β1) and incubated for 
7 days. Following the incubation period, the cells, including 
the floating cells, were harvested and washed in cold PBS. 
The cells were resuspended in 1X annexin binding buffer at 
~1x106 cells/ml, preparing a sufficient volume to be able to use 
100 µl per assay. Subsequently, 5 µl Pacific Blue annexin V 
and 1 µl 500 µM SYTOX AADvanced dead cell stain working 
solution were added to each cell suspension and incubated 
at room temperature for 30 min, protected from the light. 
Following the incubation period, 400 µl 1X annexin binding 
buffer was added to each suspension. During the analysis, the 
samples were kept on ice.
Investigating the optimal administration interval between 
PTX and TGF‑β. An immunoblotting analysis of p-Smad2/3 
was used to investigate the optimal administration interval 
between PTX and TGF-β. Following the culture period, the 
medium was replaced with RPMI‑1640 medium containing 
1% FBS and 2.5 nM PTX. Subsequently, 5 ng/ml TGF-β was 
administered after PTX using one of the following intervals; 0, 
10, 30 and 120 min. Following 60 min of the TGF-β reaction 
time as described, the cells that did not undergo apoptosis or 
the dead cells that were floating in the medium were harvested 
by trypsinization using 0.25% trypsin‑EDTA (Invitrogen), then 
washed 3 times with PBS and dissolved in RIPA buffer (Wako 
Pure Chemical Industries, Ltd., Osaka, Japan) containing 
protease and phosphatase inhibitors (Sigma-Aldrich). The 
protein concentration of each sample was measured using a 
BCA protein assay kit (Thermo Scientific). The total protein 
was measured using a spectrophotometer. The extracted 
protein was used for the western blot analysis. In this analysis, 
45 µg protein from each sample was loaded onto 12.5% 
sodium dodecyl sulfate-polyacrylamide gels (SDS-PAGE) 
and the proteins were transferred to a polyvinylidene difluo-
ride (PVDF) membrane by the semi-dry blotting method 
using blotting solution (hydroximethyl; Ez Fast Blot; ATTO 
Corporation, Tokyo, Japan). The membrane was washed for 
10 min with blocking solution (0.1% Tween‑20; Ez Block; 
ATTO Corporation), blocked at room temperature for 30 min 
again using blocking solution and then washed with washing 
solution (0.1% Tween‑20; Ez Wash; ATTO Corporation). The 
blots were incubated for 8 h at room temperature with a goat 
anti-p-Smad2/3 antibody diluted at 1:500 with washing solu-
tion. Subsequent to being washed with a gradient buffer (Ez 
Wash), the membranes were incubated with an HRP-conjugated 
anti-goat IgG antibody for 1 h at room temperature. The 
antibody-antigen complex was detected using the ECL Plus 
Western blotting detection system (GE Healthcare UK, Ltd., 
Buckinghamshire, UK), according to the supplier's recom-
mendations.
Immunocytochemistry. The expression of E-cadherin, 
N-cadherin, vimentin and β-catenin in the ICC cells was 
examined immunocytochemically using their respective 
primary antibodies. The cells were seeded on Lab-Tek 
chamber slides (Nalge Nunc International, Penfield, NY, 
USA) with PTX and/or TGF-β (5 ng/ml TGF-β; 1 nM 
PTX + 5 ng/ml TGF-β; 2.5 nM PTX + 5ng/ml TGF-β; or 
5 nM PTX + 5 ng/ml TGF-β) and incubated for 7 days at 
37˚C in a humid atmosphere of 5% CO2/95% air. Following 
the incubation period, the waste solution was discarded and 
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the coverslips with the cells were then fixed with methanol 
and acetone 1:1 (v/v) for 10 min. 
Immunostaining was performed as described. Briefly, the 
slides were blocked with normal goat serum [5% in phos-
phate-buffered saline (PBS)] and incubated with each primary 
mouse monoclonal antibody, as described previously, for 6 h 
at room temperature. The slides were washed in PBS and the 
immunoreactivity was visualized by incubating the slides 
with a goat anti-mouse IgG antibody conjugated with Alexa 
Fluor 488 (Invitrogen; 1:400) for 1 h at room temperature. The 
slides were counterstained with bis-benzimide (100 ng/ml; 
Hoechst 33258; Sigma-Aldrich) to visualize the nuclei. The 
slides were then examined under a fluorescence microscope 
(BZ-9000 Biorevo; Keyence, Osaka, Japan). In addition, 
the cadherin switch was examined by double staining. A 
primary rabbit monoclonal antibody against N-cadherin 
was administered and incubated for 6 h at room temperature 
following incubation with the primary mouse monoclonal 
antibody against E-cadherin and being washed in PBS. A goat 
anti-mouse and anti-rabbit IgG antibody were used at the same 
time.
Immunoblot analysis. The processes for harvesting and 
measuring the protein concentration and for the blotting 
technique were the same as described previously. Briefly, each 
sample used 45 µg protein and the 4 antibodies for E‑cadherin 
(1:100), N-cadherin (1:100), vimentin (1:500) and α-SMA 
(1:500) in the western blot analysis. The antibodies were used 
as EMT markers to measure the up or downregulation of the 
expression in the CCKS-1 cells that were incubated in the 
medium with an added concentration of PTX and/or TGF-β1 
(control, 5 ng/ml TGF-β1; 1 nM PTX + 5 ng/ml TGF-β1; 
2.5 nM PTX + 5 ng/ml TGF-β1; and 5 nM PTX + 5ng/ml 
TGF-β1) for 8 h at room temperature.
Results
Determining the optimal PTX concentration. In the cell 
proliferation assay, PTX inhibited cell proliferation at 
concentrations of ≥2.5 nM and significantly inhibited cell 
proliferation at concentrations of ≥5 nM compared with the 
control (Fig 1). The percentage of the dead and apoptotic 
cells markedly increased when using a concentration of 
5 nM or higher in the cell death assay (Fig. 2). Based on 
these results, the cytotoxic concentration of PTX for CCKS-1 
was estimated to be 2.5-5nM. Therefore, the concentrations 
that were used in the subsequent experiments were 1, 2.5 
and 5 nM PTX. A concentration of 5 nM PTX was included 
in order to observe whether EMT is inhibited at a cytotoxic 
concentration.
Morphological investigation. The untreated CCKS-1 cells 
displayed a cobblestone-like morphology and cell-to-cell 
adhesion was intact. However, the TGF-β1-treated CCKS-1 
cells developed a spindle-shaped morphology, the cell-to-cell 
adhesions became weak and the cells were scattered. The cells 
that were treated with low-dose PTX were assembled closely, 
although the morphology did not completely resemble the 
cobblestone-like appearance of the control cells. The morpho-
logical changes were concentration-dependent (Fig. 3).
Immunofluorescence investigation. In the investigation of 
the cadherin switch and vimentin expression, the untreated 
CCKS-1 cells predominantly expressed E-cadherin on 
the cell membrane and weakly expressed vimentin. The 
TGF-β1-treated CCKS-1 cells expressed N-cadherin and 
vimentin strongly. However, the expression of E-cadherin in 
the low-dose PTX-treated CCKS-1 cells was stronger than 
the expression of N-cadherin, and the vimentin expression 
was weak, which was consistent with the control. Similarly, 
the untreated CCKS-1 cells expressed β-catenin on the cell 
membrane and in the cytoplasm. In the TGF-β1-treated 
CCKS-1 cells, β-catenin expression shifted partially to the 
nucleus (arrows), but the administration of low-dose PTX 
inhibited this movement (Fig. 4).
Immunoblot investigation. The untreated CCKS-1 cells 
strongly expressed E-cadherin and weakly expressed the 
mesenchymal markers. In contrast, the TGF-β1-treated 
CCKS-1 cells expressed the mesenchymal markers strongly 
and E-cadherin weakly. However, the low-dose PTX weakened 
the expression of the mesenchymal markers and enhanced 
E-cadherin expression in a concentration dependent manner 
(Fig. 5).
Figure 1. Treatment of CCKS‑1 cells with various concentrations of PTX. PTX was observed to start inhibiting cell proliferation at concentrations of ≥2.5 nM 
and significantly inhibit cell proliferation at concentrations of ≥5 nM. The data are represented as the mean ± SD of three independent experiments. Statistically 
significant differences were determined by Welch's t‑test. #P<0.01 vs. control. PTX, paclitaxel.
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Discussion
EMT is a concept by Hay et al that is observed during the 
mesenchymal transition of primitive epidermal cells during 
gastrulation (19). In subsequent studies, EMT has been classi-
fied into three subtypes (20). Type 1 EMT is involved during 
developmental stages, including gastrulation, the migration of 
neural crest cells from neuroepithelial cells and the formation 
of endocardial cushion tissue from cardiac endothelial cells. 
Type 2 EMT involves the transition of epidermal cells to 
tissue fibroblasts, which participate in wound healing, regen-
eration and fibrosis in adult tissues. Type 3 EMT involves the 
metastatic or invasive process of carcinoma. However, while 
these three processes are different, there are certain aspects 
in common in the induction of the EMT mechanism. TGF-β 
is a well-known factor to induce EMT (9,10). Although the 
detailed explanation with regard to the association between 
TGF-β signaling and EMT is skipped, the Smad pathway is 
significant to the signaling process. In brief, p-Smad2/3 forms 
heteromeric complexes with Smad4, which translocate into the 
nucleus and act as transcriptional regulators of target genes by 
interacting with other transcription factors and transcriptional 
regulators.
Recently, several anti-EMT agents have been reported in 
in vitro analyses, including vorinostat (21), panobinostat (22), 
valproic acid (23) and PTX. As discussed previously, low-dose 
PTX has been shown to inhibit fibrosis and the invasive ability of 
cancer cells in several cell lines. A low dose of PTX is considered 
to suppress the phosphorylation of Smad2/3. Although it is well 
known that PTX behaves as an anticancer agent by stabilizing 
microtubules, it is also been identified that microtubules and 
Smad 2/3 are closely connected (24). Taken together, this data 
indicates that PTX acquires anticancer abilities by regulating 
Smad 2/3, which is closely connected with the progression of all 
types of EMT. PTX, through the regulation of Smad 2/3, has the 
potential to inhibit fibrosis and the invasive abilities of cancer.
Figure 3. Morphological investigations of CCKS-1. (A) Untreated CCKS-1 cells showing a pebble-like shape with cell-cell contact. (B) CCKS-1 cells became 
spindle-shaped and the cell-cell contacts separated (5ng/ml TGF-β1). (C) Low-dose PTX lead to close cell-cell contacts and pebble-like shaped cells in contrast 
with the TGF-β1-treated cells (5ng/ml TGF-β1 + 5 nM PTX). TGF-β1, transforming growth factor-β1; PTX, paclitaxel.
  A   B   C
Figure 2. Flow cytometry of CCKS-1 cell death assay using various concentrations of PTX and/or TGF-β. The percentage of apoptotic/dead cells increased at 
concentrations of ≥5nM and were significantly increased at ≥10nM. Statistically significant differences were determined by the χ2 test. #P<0.05; ##P<0.01 vs. 
control. TGF-β1, transforming growth factor-β1; PTX, paclitaxel.
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The present study was performed based on these afore-
mentioned phenomena. PTX was observed to potentially 
inhibit EMT in CCKS-1 cells, as shown by the aspects 
of their morphology and the inhibition of the expression 
of mesenchymal markers on immunofluorescence and 
immunoblot investigations. However, it is noteworthy that 
PTX inhibited the expression of mesenchymal markers in 
a concentration-dependent manner in the immunoblotting 
investigation. The optimal PTX concentration was estimated 
at 5 nM PTX, as this was the cytotoxic concentration for 
the CCKS-1 cells. Accordingly, PTX may potentially inhibit 
EMT in low-dose and normal-dose concentrations for viable 
CCKS-1 cells. Using 10 nM concentrations of PTX to examine 
this is difficult, since few cells are able to survive in strongly 
cytotoxic concentrations, therefore, further study is required. 
Furthermore, the present study also indicates further investi-
gation is warranted into the role of the pathways that include 
Smad2/3 in EMT.
As biliary tract cancers, including cholangiocarcinoma, are 
difficult to diagnose in their early stage, there are numerous 
cases that are treated with chemotherapy. While one of the 
major chemotherapeutic regimens for biliary tract cancers is 
Figure 4. Immunofluorescence investigations of the cadherin switch (red, E‑cadherin; green, N‑cadherin). (A) Untreated CCKS‑1 cells strongly express 
E-cadherin on the cell membrane, but the administration of 5ng/ml TGF-β1 leads to the cadherin switch. (B) CCKS-1 cells strongly express N-cadherin. 
(C) CCKS-1 cells treated with low-dose PTX express E-cadherin more strongly than N-cadherin (5ng/ml TGF-β1 + 2.5nM PTX). Immunofluorescence 
investigations of β-catenin (green, β-catenin; blue, nuclei). (D) Untreated CCKS-1 cells express β-catenin on the cell membrane and cytoplasm. (E) TGF-
β1-treated CCKS-1 cells express β-catenin in the nucleus (arrow; 5ng/ml TGF-β1), but (F) low‑dose PTX inhibited those changes (5 ng/ml TGF‑β1 + 2.5nM 
PTX). Immunofluorescence investigations of vimentin. (G) Untreated CCKS‑1 cells weakly express vimentin, but (H) TGF‑β1-treated CCKS-1 cells express 
vimentin strongly (5ng/ml TGF-β1). (I) Low-dose PTX inhibits the expression of vimentin, similar to the untreated cells (5ng/ml TGF-β1 + 5 nM PTX). 
TGF-β1, transforming growth factor-β1; PTX, paclitaxel.
Figure 5. Western blot analysis of epidermal/mesenchymal markers. 
Untreated CCKS-1 cells weakly express the mesenchymal markers. However, 
TGF-β1-treated CCKS-1 cells strongly express the mesenchymal markers. 
Low-dose PTX inhibits mesenchymal change in a concentration-dependent 











HIROSE et al:  LOW-DOSE PACLITAXEL INHIBITS EMT IN A HUMAN CHOLANGIOCARCINOMA CELL LINE920
cisplatin with gemcitabine, as established by Valle et al (25), 
the median overall survival time is only 11.7 months. Other 
regimens based on 5-fluorouracil (FU), one of the major 
drugs that is used in the treatment of hepatobiliary-pancreatic 
cancers, were not shown to contribute to survival and quality 
of life (26,27). 
Furthermore, it has been reported that anti-cancer 
treatments, including chemotherapy, radiation therapy 
and radiofrequency ablation, may induce EMT in cancer 
cells (28-30). Based on these studies, major anticancer treat-
ments using anti-EMT treatments, including low-dose PTX, 
may be truly effective treatment approaches. In a previous 
study, we experienced a case of successful treatment for 
unresectable gallbradder cancer with low-dose PTX following 
the failure of gemcitabine and oral S-1 (31), which is an oral 
prodrug for 5-FU that is widely used in Japan (32).
In conclusion, though the possibility of inhibiting EMT 
using PTX for biliary tract cancers in clinical practice is 
unclear, the potential of PTX warrants further investigation.
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